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Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient 
streptozotocin diabetic mice. 
 
Abstract 
Parenteral delivery of long-Acting glucagon-like peptide-1 (GLP-1) mimetics has received much 
attention as a therapeutic option for diabetes. However, cell therapy-based GLP-1 treatments 
may provide a more physiological regulation of blood glucose. The present study assessed the 
effects of chronic GLP-1 delivery by cell therapy, using the GLP-1-secreting GLUTag cell line, 
in normoglycemic and streptozotocin-induced diabetic mice. GLUTag cell aggregates were 
transplanted into the subscapular region of mice. Over 30 days, cellular transplantation gave rise 
to encapsulated and well-vascularized growths, which contained immunoreactive GLP-1. Cell 
implantation was well tolerated and had no appreciable metabolic effects in normal mice. 
However, transplantation significantly (P<0.001) countered excessive food and fluid intake in 
diabetic mice and maintained normal body weight. Circulating glucose (P<0.01) and glucagon 
(P<0.05) were significantly reduced and plasma insulin and GLP-1 dramatically increased. This 
was associated with significantly (P<0.01) improved glucose tolerance in diabetic mice. 
Histological examination of the pancreata of these mice revealed elevations (P<0.001) in islet 
and β-cell area, with reduced (P<0.001) -cell area. Increased β-cell mass reflected the enhanced 
proliferation relative to apoptosis. These studies emphasize the potential of chronic GLP-1 
delivery by cell therapy as a potential therapeutic option for diabetes. 
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